| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098877 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
| US10835530 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
| US10517868 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
| US9918984 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(2 years from now) | |
| US11478471 | STRONGBRIDGE | NA |
Jan, 2026
(2 years from now) | |
| US11278547 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) | |
| US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) | |
Recorlev is owned by Strongbridge.
Recorlev contains Levoketoconazole.
Recorlev has a total of 7 drug patents out of which 0 drug patents have expired.
Recorlev was authorised for market use on 30 December, 2021.
Recorlev is available in tablet;oral dosage forms.
Recorlev can be used as treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative, during levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage of metformin as needed.
The generics of Recorlev are possible to be released after 02 March, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative; During levoketoconazole dosage titration for the treatment of ...
Dosage: TABLET;ORAL
RECORLEV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic